Efficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials-Reference-Cited by-同舟云学术

Efficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials

Published:2021-03 Issue:3 Volume:10 Page:2687-2698
ISSN:2224-5820
Container-title:Annals of Palliative Medicine
language:
Short-container-title:Ann Palliat Med

Author:

Chen Zheng,Jiang Shu,Li Xuechun,Zhang Jingyao,Liu Liu,Li Juan,Cao Peiyu,Xin Yong,Zhang Longzhen

Publisher

AME Publishing Company

Subject

Anesthesiology and Pain Medicine,Advanced and Specialized Nursing

Link

https://apm.amegroups.com/article/download/61988/pdf

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer;OncoTargets and Therapy;2024-08

2. The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer;Critical Reviews in Oncology/Hematology;2024-04

3. Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database;Frontiers in Oncology;2022-11-23

4. Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials;Journal of Oncology;2022-11-21

5. Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial;Journal of Cancer Research and Clinical Oncology;2022-04-28